ImmunityBio Surges After EU Approves ANKTIVA for Bladder Cancer: What Investors Need to Know Today | MarketWire

ImmunityBio's shares soar on Feb. 18, 2026, after EU approval of ANKTIVA, marking a pivotal moment for the biotech firm.